• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Savara Pharmaceuticals

edit

Savara Pharmaceuticals develops next generation pulmonary drug delivery solutions using its NanoCluster formulation technology. Dry powder and nebulizer-based medicines are formulated directly from active drug ingredients, requiring no carrier particles and little or no excipients. The aerodynamics of NanoCluster formulations are fully customizable from one to seven microns enabling high drug concentrations at specific regions of the lung, independent of the rate or depth of breath. Savara expects that NanoCluster’s unique features will produce numerous patient benefits including reduced dosage, enhanced efficacy, improved safety and increased tolerability, as well as greater patient convenience. Savara’s NanoCluster technology is currently available for evaluation and licensing.

Recent Milestones

edit

• 
  Savara Pharmaceuticals received $7.4M in Series B funding. (3/21/13)
  Posted 3/25/13 at 10:37pm via finsmes.com
• 
  Savara Pharmaceuticals received $8.6M in Series B funding. (6/12/12)
  Posted 6/12/12 at 6:47pm via finsmes.com
• 
  Savara Pharmaceuticals received $645k in Series A funding. (12/15/09)
  Posted 12/15/09 at 4:32pm via sec.gov
• 
  Savara Pharmaceuticals received $833k in Series A funding. (7/6/09)
  Posted 7/6/09 at 11:16am via onbiovc.com
• 
  Savara Pharmaceuticals added Curt Bilby as Director.
  Posted 12/15/09 at 4:34pm
• 
  Savara Pharmaceuticals added Matt Dennis as Director.
  Posted 12/15/09 at 4:34pm
• 
  Savara Pharmaceuticals added Nevan Elam as Director.
  Posted 12/15/09 at 4:34pm

Videos

Screenshots

edit

Above: Savara Pharmaceuticals
Uploaded: 10/24/09

Sources

1. Savara Pharmaceuticals, Inc.: Series A $1.0M (onbiovc.com) [edit]
2. SEc D (sec.gov) [edit]
3. Savara Pharmaceuticals Raises $8.6M in First Closing of Series B Funding (finsmes.com) [edit]
4. Savara Pharmaceuticals Closes $7.4M Second Tranche of Series B Financing (finsmes.com) [edit]